Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Michael S. May

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6187-4655; OpenAlex author ID A5041808775; NIH RePORTER profile ID 78257449. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
1
Labs led
2
Collaborators
44
Papers, trials and grants by year

2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 4 papers, 1 grant

Papers 10

  1. Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here. Co-author DOI 10.1007/s40265-026-02295-0↗
  2. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
  3. Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. Co-author DOI 10.1200/po-26-00138↗
  4. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  5. Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41588-025-02345-5↗
  6. A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX. First author DOI 10.1093/oncolo/oyad315↗
  7. Low Bacterial Biomass in Human Pancreatic Cancer and Adjacent Normal Tissue. Co-author DOI 10.3390/ijms26010140↗
  8. Smoking is Not Associated with Lung Metastasis in Pancreatic Cancer. Co-author DOI 10.1080/07357907.2023.2203747↗
  9. Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2023.12.24.573257↗
  10. Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer. First author DOI 10.3390/ijms24044238↗

Grants 1

  1. Predictive Markers of Response to and Treatment Effects of Motixafortide, Cemiplimab, Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Metastatic Pancreatic C… K38CA304069↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alexander Grenander Raufi · 7 shared papers, 2023–2026 · strength 1.42
  2. Gulam Abbas Manji · 7 shared papers, 2023–2026 · strength 1.40
  3. Jacob K.R. Jamison · 4 shared papers, 2023–2025 · strength 0.84
  4. Wungki Park · 2 shared papers, 2026 · strength 0.68
  5. Eileen Mary O'Reilly · 2 shared papers, 2026 · strength 0.68
  6. Benjamin Izar · 3 shared papers, 2025–2026 · strength 0.57
  7. Alina Cornelia Iuga · 3 shared papers, 2023–2026 · strength 0.56
  8. Kenneth P. Olive · 3 shared papers, 2023–2026 · strength 0.56
  9. Susan Elaine Bates · 2 shared papers, 2026 · strength 0.39
  10. Linda Y. Wu · 2 shared papers, 2026 · strength 0.39
  11. Michael D. Kluger · 2 shared papers, 2025–2026 · strength 0.37
  12. John A. Chabot · 2 shared papers, 2025–2026 · strength 0.37
  13. Lyndon Luk · 1 shared paper, 2024 · strength 0.24
  14. Wafik S. El‐Deiry · 1 shared paper, 2023 · strength 0.24
  15. Attila A. Seyhan · 1 shared paper, 2023 · strength 0.24
  16. Alfred I. Neugut · 1 shared paper, 2023 · strength 0.20
  17. Emanuel F. Petricoin · 1 shared paper, 2026 · strength 0.20
  18. Brian William Labadie · 1 shared paper, 2026 · strength 0.20
  19. Andrea Califano · 1 shared paper, 2026 · strength 0.20
  20. Urszula N. Wasko · 1 shared paper, 2026 · strength 0.20
  21. Howard P. Safran · 1 shared paper, 2026 · strength 0.20
  22. Li Li · 1 shared paper, 2026 · strength 0.19
  23. Beth Schrope · 1 shared paper, 2026 · strength 0.19
  24. Tito Fojo · 1 shared paper, 2026 · strength 0.19
  25. Benjamin D. Greenbaum · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.